Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
复制标题
DOI：
10.1038/s41586-021-03777-9
复制
发表时间：
2021-07-08
期刊：
影响因子：
64.8
通讯作者：
Schwartz, Olivier
中科院分区：
文献类型：
--
作者：
Planas, Delphine;Veyer, David;Schwartz, Olivier
2020年10月在印度发现了SARS-CoV-2 B.1.617谱系（1-5）。从那时起，它已成为印度和英国的一些地区的主导地位，并已蔓延到许多其他国家（6）。该谱系包括三种主要亚型（B1.617.1、B.1.617.2和B.1.617.3），它们在SARS-CoV-2刺突蛋白的N-末端结构域（NTD）和受体结合结构域（RBD）中含有不同的突变，这些突变可能增加这些变体的免疫逃避潜力。B.1.617.2-也称为Delta变体-被认为比其他变体传播得更快。在这里，我们从一名从印度返回法国的COVID-19患者身上分离出了Delta变异的传染性菌株。我们检测了该毒株对单克隆抗体的敏感性，以及对COVID-19康复者（以下简称康复者）或接种COVID-19疫苗者血清中存在的抗体的敏感性，然后将该毒株与其他SARS-CoV-2毒株进行了比较。Delta变体对一些抗NTD和抗RBD单克隆抗体（包括bamlanivimab）的中和具有抗性，并且这些抗体显示与刺突蛋白的结合受损。从症状发作后长达12个月的恢复期个体中采集的血清对Delta变异体的效力比Alpha变异体低4倍（B.1.1.7）。接受过一剂辉瑞或阿斯利康疫苗的个体的血清对Delta变体几乎没有明显的抑制作用。接种两剂疫苗后，95%的个体产生了中和反应，对Delta变体的滴度比对Alpha变体的滴度低3 - 5倍。因此，Delta变体的扩散与靶向刺突蛋白的非RBD和RBD表位的抗体的逃逸相关。
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India(1-5). Since then, it has become dominant in some regions of India and in the UK, and has spread to many other countries(6). The lineage includes three main subtypes (B1.617.1, B.1.617.2 and B.1.617.3), which contain diverse mutations in the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein that may increase the immune evasion potential of these variants. B.1.617.2-also termed the Delta variant-is believed to spread faster than other variants. Here we isolated an infectious strain of the Delta variant from an individual with COVID-19 who had returned to France from India. We examined the sensitivity of this strain to monoclonal antibodies and to antibodies present in sera from individuals who had recovered from COVID-19 (hereafter referred to as convalescent individuals) or who had received a COVID-19 vaccine, and then compared this strain with other strains of SARS-CoV-2. The Delta variant was resistant to neutralization by some anti-NTD and anti-RBD monoclonal antibodies, including bamlanivimab, and these antibodies showed impaired binding to the spike protein. Sera collected from convalescent individuals up to 12 months after the onset of symptoms were fourfold less potent against the Delta variant relative to the Alpha variant (B.1.1.7). Sera from individuals who had received one dose of the Pfizer or the AstraZeneca vaccine had a barely discernible inhibitory effect on the Delta variant. Administration of two doses of the vaccine generated a neutralizing response in 95% of individuals, with titres three- to fivefold lower against the Delta variant than against the Alpha variant. Thus, the spread of the Delta variant is associated with an escape from antibodies that target non-RBD and RBD epitopes of the spike protein.